Healthcare / Drug Manufacturers - Specialty & GenericBSE
$74.90
-5.44 (-6.77%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 17%
FCF escenarios
weak_data · normalized FCF $-30.3M · quality 39.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
36/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$224M
P/E
25.2x
↑EV/EBITDA
19.8x
↑ROE
8.0%
↑Gross Margin
24.8%
↓Debt/Equity
0.36
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+2.1%
FCF CAGR
—
FCF margin
-25.5%
FCF / Net income
-4.40x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $150.0M · net income $8.7M · FCF $-38.2M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $150.0M | $150.0M | $151.9M | $120.7M | $140.9M |
| Net Income | $8.7M | $8.7M | $7.5M | $5.8M | $8.0M |
| EBITDA | $13.0M | $13.0M | $11.6M | $9.5M | $11.8M |
| EPS | 2.90 | 2.90 | 2.50 | 1.93 | 2.69 |
| Gross Margin | 24.8% | 24.8% | 22.9% | 25.5% | 24.0% |
| Operating Margin | 5.9% | 5.9% | 5.2% | 5.2% | 6.8% |
| Net Margin | 5.8% | 5.8% | 4.9% | 4.8% | 5.7% |
| Balance Sheet | |||||
| Debt/Equity | 0.36 | 0.36 | — | 0.10 | — |
| Cash Flow | |||||
| Free Cash Flow | $-38.2M | $-38.2M | $20.9M | $-30.3M | $30.6M |
| Returns | |||||
| ROE | 8.0% | 8.0% | 7.5% | 6.3% | 9.4% |
| Valuation | |||||
| P/E | 25.22 | 25.22 | — | — | — |
| EV/EBITDA | 19.80 | 19.80 | — | — | — |
| P/B | 2.08 | 2.08 | — | — | — |
| Growth & Yield | |||||
| Revenue Growth | -1.3% | -1.3% | 25.8% | -14.3% | — |
| EPS Growth | 16.0% | 16.0% | 29.5% | -28.3% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
31.8%
EPS terminal req.
$6.65
Spread vs growth
-15.8%
5Y implied EPS CAGR
22.6%
EPS terminal req.
$8.04
Spread vs growth
-6.6%
10Y implied EPS CAGR
16.1%
EPS terminal req.
$12.95
Spread vs growth
-0.1%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+0.8%
Start / end P/E
29.7x → 25.8x
EPS bridge
2.50 → 2.90
Residual
-2.1%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.